Garde S, Chodisetti PK, Reddy M, Peptidoglycan
Quick Answer: Allodynia is not listed as an adverse effect in FDA-approved prescribing information for semaglutide products
The 23 online screens cover demographics, comorbidities, family and surgery history, medications, allergies, lifestyle, race/ethnicity, and address but they do not ask the GLP-1-specific FDA-black-box questions (MTC, MEN-2, pancreatitis personal history) and they do not let the patient select a medication
In the inflammation substudy, researchers looked at patients in the STEP-HFpEF program with obesity-related HFpEF to determine the effect of semaglutide on HF symptoms and physical limitations in people with varying levels of inflammation at baseline